Allelic frequencies of 3' Ig heavy chain locus enhancer HS1,2-A associated with Ig levels in patients with schizophrenia

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 1, 2009, Pages 115-123

  Frezza, Domenico ^a   Giambra, V ^a,b   Mattioli, C ^a   Piccoli, K ^a   Massoud, R ^a   Siracusano, A ^a   Di Giannantonio, M ^b   Birshtein, B K ^c   Rubino, I A ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

2 alleles; EMSA; HSI; Ig3' regulatory region; NF B; Pharmacologic antipsychotic treatment; Plasma Ig levels

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; DEOXYRIBONUCLEASE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; TRANSCRIPTION FACTOR SP1;

ADULT; ARTICLE; B LYMPHOCYTE; BINDING SITE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENHANCER REGION; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 62649145611     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200113     Document Type: Article

References (23)

1. Sen R, Oltz E. Genetic and epigenetic regulation of IgH gene assembly. Curr Opin Immunol 2006; 18: 237-242.
2. Khamlichi AA, Pinaud E, Decourt C, Chauveau C, Cogne M. The 3′IgH regulatory region: a complex region in search for a function. Adv Immunol 2000; 75:317-345.
3. Mills FC, Harindranath N, Mitchell M, Max EE. Enhancer complexes located downstream of both human immunoglobulin Calpha genes. J Exp Med 1997; 186:845-858.
4. Guglielmi L, Truffinet V, Magnoux E, Cogne M, Denizot Y. The polymorphism of the locus control region lying downstream the human IgH locus is restricted to hs1,2 but not to hs3 and hs4 enhancers. Immunol Lett 2004; 94:77-81.
5. Giambra V, Fruscalzo A, Giufre' M, Martinez- Labarga C, Favaro M, Rocchi M, Frezza D. Evolution of human IgH3′EC duplicated structures: both enhancers HS1,2 are polymorphic with variation of transcription factor's consensus sites. Gene 2005; 346:105-14.
6. Giambra V, Martinez-Labarga C, Giufré M, et al. Immunoglobulin enhancer HS1,2 polymorphism: a new powerful anthropogenetic marker. Ann Hum Genet 2006; 70:946-50.
7. Aupetit C, Drouet M, Pinaud E, Denizot Y, Aldigier JC, Bridoux F, Cogné M. Alleles of the alpha-1 immunoglobulin gene 3′ enhancer control evolution of IgA nephropathy toward renal failure. Kidney Internat 2000; 58:966-71.
8. Frezza D, Giambra V, Cianci R, et al. Increased frequency of the immunoglobulin enhancer HS1,2 allete *2 in coeliac disease. Scand J Gastroenterol 2004; 39:1083-7.
9. Frezza D, Giambra V, Tolusso B, et al. Polymorphism of immunoglobulin (Ig) enhancer element HS1,2A: allele *2 associates with Systemic Sclerosis. Comparison with HLA-DR and DQ alleles frequency. Ann Rheum Dis 2007; 66:1210-5.
10. Cianci R, Giambra V, Mattioli C, et al. Increased frequency of Ig heavy chain HS1,2-A Enhancer *2 allele in dermatitis herpetiformis, plaque psoriasis and psoriatic arthritis. J Invest Dermat 2008; 128: 1920-4.
11. Eaton WW, Byrne M, Ewald H, Mors O, Chen C-Y, Agerbo E, Mortensen PB. Association of schizophrenia with autoimmune diseases: linkage of Danish National Registers. Am J Psychiatry 2006; 163:521-28.
12. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review. Biol Psychiatry 2008; 63:801-8.
13. Knight JG, Menkes DB, Highton J, Adams DD. Rationale for a trial of immunosuppressive therapy in acute schizophrenia. Mol Psychiatry 2007; 12:424-31.
14. Rothermundt M, Arolt V, Bayer TA. Review of immunological and immunopathological findings in schizophrenia. Brain Behav Immunity 2001; 15:319-39.
15. Strous RD, Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun 2006; 27:71-80.
16. Hinze-Selch D, Becker EW, Stein GM, Berg PA, Mullington J, Holsboer F, Pollmacher T. Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuro-psycho-pharmacology. 1998; 19: 114-22.
17. Sirota P, Meiman M, Herschko R, Bessler H. Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients. Psychiatry Res 2005; 134:151-9.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Press. 1994.
19. First MB, Spitzer RL, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders. Patient Edition 1996 (SCID-I-P). New York: Biometrics Research Dept, New York State University.
20. Schreiber E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 1989; 17:6419.
21. Fujita T, Nolan GP, Ghosh S, Baltimore D. Independent modes of transcriptional activation by the p50 and p65 subunits of NF-kappa B. Genes Dev 1992; 6:775-87.
22. Ramchand R, Wei J, Ramchand CN, Hemmings GP. Increased serum ige in schizophrenic patients who responded poorly to neuroleptic treatment. Life Sci 1994; 54:1579-84.
23. Michaelson JS, Singh M, Birshtein BK. B cell lineage-specific activator protein (BSAP). A player at multiple stages of B cell development. J Immunol 1996; 156:2349.